Interindividual variation in the isomerization of 4- hydroxytamoxifen by human liver microsomes: Involvement of cytochromes P450

Carcinogenesis

Volumn 15, Issue 12, 1994, Pages 2733-2738

  Williams, M L ^a   Lennard, M S ^a   Martin, I J ^a,b   Tucker, G T ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Upjohn Laboratories Europe   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; CYTOCHROME P450; PROADIFEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TAMOXIFEN; TAMOXIFEN DERIVATIVE;

ADULT; ARTICLE; BREAST CANCER; CIS TRANS ISOMERISM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; MALE; PRIORITY JOURNAL;

ADULT; BIOTRANSFORMATION; COMPARATIVE STUDY; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE; FEMALE; HUMAN; ISOMERISM; KETOCONAZOLE; MALE; MICROSOMES, LIVER; MIDDLE AGE; NADP; PROADIFEN; SUPPORT, NON-U.S. GOV'T; TAMOXIFEN; VARIATION (GENETICS);

EID: 0028596462     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/15.12.2733     Document Type: Article

References (37)

1. British Medical Association of Great Britain (1990) British National Formulary. BMA, London, UK
2. Catherino, W.H. and Jordan, V.C. (1993) A risk-benefit assessment of taxoxifen therapy. Drug Safety, 8, 381-397
3. Powles, T.J., Tillyer, C.R., Jones, A. L., Ashley, S.E., Treleaven, J., Davey, J.B. and McKcnna, J.A. (1990) Prevention of breast cancer with tamoxifen-an update on the Royal Marsden Hospital pilot programme. Eur. J. Cancer., 26, 680-684
4. Buckley, M.T. and Goa, K.L. (1989) Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Clin. Pharmacokinet., 37, 451-490
5. Wolf, D.M., Langan-Fahay, S.M., Parker, CJ., McCague, R. and Jordan, V.C. (1993) Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. J. Natl Cancer Inst., 85, 806-812
6. Lien, E.A., Solheim, E. and Ueland, P. (1991) Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res., 51, 4837-4844
7. Osborne, C.K., Wiebe, VJ., McGuire, W.L., Ciocca, D.R. and DcGrcgorio, M.W. (1992) Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J. Cltn. Oncol., 10, 304-310
8. Murphy, C.S., Langen-Faltey, S.M., McCague, R. and Jordan, V.C. (1990) Structure-function relationships of hydroxylated metabolites of tamoxifen that control die proliferation of estrogen-responsive T47D breast cancer cells in vitro. Mol. Pharmacol., 38, 737-743
9. Coezy, E., Borgna, J.L. and Rochefort, H. (1982) Tamoxifen and metabolites in MCF-7 cells: correlation between binding to estrogen receptors and inhibition of cell growth. Cancer Res., 42, 317-323
10. Kalzenellenbogen, B.S., Norman, MJ., Eckert, R.L., Peltz, S.W. and Mangel, W.F. (1984) Bioactivities, estrogen receptor interactions, and plasminogen activator inducing activities of tamoxifen and 4-hydroxytamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res., 44, 112-119
11. Jordan, V.C., Koch, R., Langan, S. and McCague, R. (1988) Ligand interaction at the estrogen receptor to program antiestrogen action: A study with nonsteroidal compounds in vitro. Endocrinology, 122, 1449-1454
12. Osbome, C.K., Coranado, E., Allred, D.C., Wiebe, V. and Degregorio, M. (1991) Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J. Natl Cancer Inst., 83, 1477-1482
13. Johnston, S.R.D., Haynes, B.P., Smith, I.E., Jarman, M., Sacks, N.P.M., Ebbs, S.R. and Dowsett, M. (1993) Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet., 342, 1521-1522
14. Jordan, V.C., Haldemann, B. and Allen, K.E. (1981) Geometric isomers of triphenylethylenes and antiestrogen action. Endocrinology, 108, 1353-1361
15. Mani, C. and Kupfcr, D. (1991) Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liven possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res., 51, 6052-6058
16. Mani, C., Gelboin, H.V., Park, S.S., Pearce, R., Parkinson A and Kupfer, D. (1993) Metabolism of the antimammary cancer antiestrogen agent tamoxifen. Drug Metab. Dispos., 21, 645-656
17. Jacolet, F., Simon, I., Dreano, Y., Beaune, P., Riche, C. and Berthou, F. (1991) Identification of the cytochrome P450II1A family as the enzymes involved in the A'-demethylation of tamoxifen in human liver microsomes. Biochem. ParmacoL, 41, 1911-1919
18. Loser, R., Seibel, K. and Huber, HJ. (1988) Pharmacological activities of droloxifene isomers. Anticancer Res., 8, 1271-1274
19. Otton, S.V., Crewe, H.K., Lennard, M.S., Tticker, G.T. and Woods, H.F. (1988) Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J. Pharmacol. Exp. Ther., 511, 242-247
20. Lowry, O.H., Rosebrough J.J.J., Farr, A.L. and Randall, RJ. (1951) Protein measurement with the Folin phenol reagent. J. BioL Chem., 193, 265-275
21. Jank J., Kem, D., Huber, HJ. and Stanislaus, F. (1987) Direct determination of droloxifene using HPLC with pre-column switching, post-column photochemical derivatisation and fluorescence detection. In Proceedings of the 3rd European Congress on Biopharmacology and Pharmokinetics, pp. 511-520
22. Martin JJ., Duncan J.J.I., Parton A.H., Speed, W. and King, LJ. (1993) The use of thermospray mass spectrometry (TSP/LC/MS) to identify the metabolites of 2-(di-n-propylamino)tetralin (DPAT) in isolated rat hepatocytes. Br. J. Clin. Pharmacol, 36, 163p-164p
23. Katzenellenbogen, J.A., Carlson, K.E. and Katzenellenbogen, B.S. (1985) Facile geometric isomerisation of phenolic non-steroidal estrogens and antiestrogens: limitations to the interpretation of experiments characterising the activity of individual isomers. J. Steroid Biochem., 22, 589-590
24. Tucker, G.T., Lennard, M.S., Ellis, S.W., Woods, H.F., Cho, A.K., Lin, L.Y., Hiratsuka, A., Schmitz, D.A. and Chu, T.Y.Y. (1994) The demethylenation of methylenedioxymethamphetamine (‘ecstasy’) by debrisoquine hydroxylase (CYP2D6). Biochem. Pharmacol., 47, 1151-1156
25. Goldstein J. A., Faletto, M.B., Romkes-Sparks, M., Sullivan, T., Kitareewan, S., Raucy, J.L., Lasker, J.M. and Ghanayem, B.I. (1994) Evidence that CYP2C19 is the major (57-mephenytoin 4'-hydroxylase in humans. Biochemistry, 33, 1743-1752
26. Wrighton, S.A., Brian, W.R., Sari, M.A., Iwasaki, M., Guengerich, F.P., Raucy, J.L., Molowa, D.T. and Vandenbranden, M. (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P450I1IA5 (HLp3). Mol. Pharmacol, 38, 207-213
27. Smith, GJ., Bloomer, J.C., Ayrton AD., Clarke, S.E. and Chenery, RJ. (1993) The use of ketoconazole as a potent and specific inhibitor of cytochrome P4503A in vitro. In Proceedings of the Sth Stowe School Symposium on Drug Metabolism, abstract no. P27
28. Koymans, L., Donneop Den Kelder, G.M., Te Koppele, J.M. and Vermeulen J.J.P.E. (1993) Generalised cytochrome P450-mediated oxidation reactions in aromatic substrates with activated N-H, O-H, C-H, or S-H substituents. Xenobiotica, 23, 633-648
29. Sykes, P. (1988) A Guidebook to Mechanism in Organic Chemistry, 6th Edn. Longman, Cambridge, UK, pp. 150-159
30. Ghabrial, H., Prakash, C., Tacke, U.G., BJair, I.A. and Wilkinson, G.R. (1991) Geometric isomerisation of doxepin during its;V-demethylation in humans. Drug Metab. Dispos., 19, 596-599
31. Shimada, J., Hori, S., Oguma, T., Yoshikawa, T., Yamamoto, S., Nishikawa, T. and Yamada, H. (1993) Effects of protein binding on the isomerisation of ceftibutin. J. Pharm. Sci., 82, 461-465
32. Baustein, C.L. and Mikkelson, TJ. (1986) Analysis of clomiphene isomers in human plasma and detection of metabolites using reversed-phase chromatography and fluorescence detection. J. Pharm. Biomed. Anal, 4, 237-246
33. Osborne, C.K. (1993) Mechanisms for tamoxifen resistance in breast cancer possible role of tamoxifen metabolism. J. Steroid. Biochem. Mol. Biol., 47, 83-89
34. Plowman, P.N. (1993) Tamoxifen as adjuvant therapy in breast cancer. Drugs. 46, 819-833
35. Potter, G.A., McCague, R. and Jarman, M. (1994) A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis, 15, 439-442
36. White, I.N.H., Matteis, F., Davies, A., Smith, L.L., Crofton-Sleigh, C., Venitt, S., Hewer A and Phillips, D.H. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cell lines. Carcinogenesis, 13, 2197-2203
37. Grill, HJ. and Pollow, K. (1991) Pharmacokinetics of droloxifene and its metabolites in breast cancer patients. Am. J. Clin. Oncol, 14 (suppl. 2), 21-29